104 related articles for article (PubMed ID: 3752949)
21. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
22. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Harris AL; Powles TJ; Smith IE
Cancer Res; 1982 Aug; 42(8 Suppl):3405s-3408s. PubMed ID: 7083207
[TBL] [Abstract][Full Text] [Related]
23. The effects of tamoxifen on the female genital tract.
Senkus-Konefka E; Konefka T; Jassem J
Cancer Treat Rev; 2004 May; 30(3):291-301. PubMed ID: 15059652
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
[TBL] [Abstract][Full Text] [Related]
25. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Clin Biochem; 2007 Jun; 40(9-10):623-8. PubMed ID: 17425952
[TBL] [Abstract][Full Text] [Related]
26. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
[TBL] [Abstract][Full Text] [Related]
27. [Aminoglutethimide therapy in advanced breast cancer].
Kühböck J; Ludwig H; Pötzi P; Zielinski C
Wien Med Wochenschr; 1985 Dec; 135(23-24):608-11. PubMed ID: 4096007
[TBL] [Abstract][Full Text] [Related]
28. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
29. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study.
Hoogstraten B; Fletcher WS; Gad-el-Mawla N; Maloney T; Altman SJ; Vaughn CB; Foulkes MA
Cancer Res; 1982 Nov; 42(11):4788-91. PubMed ID: 7127314
[TBL] [Abstract][Full Text] [Related]
33. Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
Powles TJ; Gordon C; Coombes RC
Cancer Res; 1982 Aug; 42(8 Suppl):3458s-3460s. PubMed ID: 7044528
[TBL] [Abstract][Full Text] [Related]
34. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
35. [Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review].
Cikes M
Schweiz Med Wochenschr; 1983 Mar; 113(11):382-91. PubMed ID: 6342129
[TBL] [Abstract][Full Text] [Related]
36. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
37. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
38. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
[TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
[TBL] [Abstract][Full Text] [Related]
40. Endocrine therapy monitored by hormone cytological examination in advanced female breast cancer.
Iglódi F
Ther Hung; 1989; 37(4):205-8. PubMed ID: 2631288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
